PharmaShots | Incisive News in 3 Shots

Subscribe Now

Multiple Indications

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

April 5, 2021

Bayer Signs a Research and License Agreement with Curadev to Develop Novel STING Antagonists Across Multiple Indications

Bayer Signs a Research and License Agreement with Curadev to Develop Novel STING Antagonists Across Multiple Indications

March 23, 2020

Merck Reports FDA's Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications

Merck Reports FDA's Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications

July 9, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us